Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities

NCT01906866 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

125

Enrollment

INDUSTRY

Sponsor class

Conditions

Sleep Disorders

Interventions

DRUG: Circadin 2/5/10 mg
DRUG: Placebo

Sponsor

Neurim Pharmaceuticals Ltd.